Skip to main content
SpringerLink
Log in

Alcohol and HCV: Implications for Liver Cancer

  • Conference paper
  • First Online:
Biological Basis of Alcohol-Induced Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 815))

Abstract

Liver cancers are one of the deadliest known malignancies which are increasingly becoming a major public health problem in both developed and developing countries. Overwhelming evidence suggests a strong role of infection with hepatitis B and C virus (HBV and HCV), alcohol abuse, as well as metabolic diseases such as obesity and diabetes either individually or synergistically to cause or exacerbate the development of liver cancers. Although numerous etiologic mechanisms for liver cancer development have been advanced and well characterized, the lack of definite curative treatments means that gaps in knowledge still exist in identifying key molecular mechanisms and pathways in the pathophysiology of liver cancers. Given the limited success with current therapies and preventive strategies against liver cancer, there is an urgent need to identify new therapeutic options for patients. Targeting HCV and or alcohol-induced signal transduction, or virus–host protein interactions may offer novel therapies for liver cancer. This review summarizes current knowledge on the mechanistic development of liver cancer associated with HCV infection and alcohol abuse as well as highlights potential novel therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O’connor JK, Goldstein RM (2008) Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) 21:266–280

    Google Scholar 

  2. Morgan TR, Mandayam S, Jamal MM (2004) Alcohol and hepatocellular carcinoma. Gastroenterology 127:S87–S96

    CAS  PubMed  Google Scholar 

  3. Sanyal AJ, Yoon SK, Lencioni R (2010) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 15(Suppl 4):14–22

    PubMed  Google Scholar 

  4. Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM (2013) Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 102:74–83

    CAS  PubMed  Google Scholar 

  5. Levrero M (2006) Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834–3847

    CAS  PubMed  Google Scholar 

  6. Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis C virus particles. Trends Microbiol 19:95–103

    CAS  PubMed  Google Scholar 

  7. O’Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology (2010) Alcoholic liver disease. Hepatology 51:307–328

    PubMed  Google Scholar 

  8. Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ (2011) Treatment of alcoholic liver disease. Therap Adv Gastroenterol 4:63–81

    PubMed Central  PubMed  Google Scholar 

  9. Szabo G, Lippai D (2012) Molecular hepatic carcinogenesis: impact of inflammation. Dig Dis 30:243–248

    PubMed  Google Scholar 

  10. Machida K (2010) TLRs, alcohol, HCV, and tumorigenesis. Gastroenterol Res Pract 2010:518674

    PubMed Central  PubMed  Google Scholar 

  11. Koike K, Tsutsumi T, Miyoshi H, Shinzawa S, Shintani Y, Fujie H, Yotsuyanagi H, Moriya K (2008) Molecular basis for the synergy between alcohol and hepatitis C virus in hepatocarcinogenesis. J Gastroenterol Hepatol 23(Suppl 1):S87–S91

    CAS  PubMed  Google Scholar 

  12. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS (1996) Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 91:498–505

    CAS  PubMed  Google Scholar 

  13. Schiff ER (1999) The alcoholic patient with hepatitis C virus infection. Am J Med 107:95S–99S

    CAS  PubMed  Google Scholar 

  14. Tanaka T, Yabusako T, Yamashita T, Kondo K, Nishiguchi S, Kuroki T, Monna T (2000) Contribution of hepatitis C virus to the progression of alcoholic liver disease. Alcohol Clin Exp Res 24:112S–116S

    CAS  PubMed  Google Scholar 

  15. Regev A, Jeffers LJ (1999) Hepatitis C and alcohol. Alcohol Clin Exp Res 23:1543–1551

    CAS  PubMed  Google Scholar 

  16. Day CP (2001) Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis. Gut 49:750–751

    CAS  PubMed Central  PubMed  Google Scholar 

  17. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107

    CAS  PubMed  Google Scholar 

  18. Stickel F, Schuppan D, Hahn EG, Seitz HK (2002) Cocarcinogenic effects of alcohol in hepatocarcinogenesis. Gut 51:132–139

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Enomoto N, Ikejima K, Yamashina S, Hirose M, Shimizu H, Kitamura T, Takei Y, Sato And N, Thurman RG (2001) Kupffer cell sensitization by alcohol involves increased permeability to gut-derived endotoxin. Alcohol Clin Exp Res 25:51S–54S

    CAS  PubMed  Google Scholar 

  20. Garcia-Tsao G, Wiest R (2004) Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 18:353–372

    PubMed  Google Scholar 

  21. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG (2001) The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48:206–211

    CAS  PubMed Central  PubMed  Google Scholar 

  22. Purohit V, Bode JC, Bode C, Brenner DA, Choudhry MA, Hamilton F, Kang YJ, Keshavarzian A, Rao R, Sartor RB, Swanson C, Turner JR (2008) Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol 42:349–361

    CAS  PubMed Central  PubMed  Google Scholar 

  23. Szabo G, Bala S (2010) Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 16:1321–1329

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Petrasek J, Mandrekar P, Szabo G (2010) Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract 2010:pii: 710381

    Google Scholar 

  25. Szabo G, Aloman C, Polyak SJ, Weinman SA, Wands J, Zakhari S (2006) Hepatitis C infection and alcohol use: a dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res 30:709–719

    CAS  PubMed  Google Scholar 

  26. Protzer U, Maini MK, Knolle PA (2012) Living in the liver: hepatic infections. Nat Rev Immunol 12:201–213

    CAS  PubMed  Google Scholar 

  27. Horner SM, Gale M Jr (2013) Regulation of hepatic innate immunity by hepatitis C virus. Nat Med 19:879–888

    CAS  PubMed  Google Scholar 

  28. Heydtmann M (2009) Macrophages in hepatitis B and hepatitis C virus infections. J Virol 83:2796–2802

    CAS  PubMed Central  PubMed  Google Scholar 

  29. Liu BS, Janssen HL, Boonstra A (2012) Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. Eur J Immunol 42:2431–2440

    CAS  PubMed  Google Scholar 

  30. Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, Cormier M, Szabo G (2006) Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 177:6758–6768

    CAS  PubMed  Google Scholar 

  31. Fan Z, Huang XL, Kalinski P, Young S, Rinaldo CR Jr (2007) Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 14:1127–1137

    CAS  PubMed Central  PubMed  Google Scholar 

  32. MacDonald AJ, Semper AE, Libri NA, Rosenberg WM (2007) Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells. Clin Exp Immunol 148:494–500

    CAS  PubMed Central  PubMed  Google Scholar 

  33. Kanto T, Inoue M, Miyatake H, Sato A, Sakakibara M, Yakushijin T, Oki C, Itose I, Hiramatsu N, Takehara T, Kasahara A, Hayashi N (2004) Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 190:1919–1926

    PubMed  Google Scholar 

  34. Bala S, Tang A, Catalano D, Petrasek J, Taha O, Kodys K, Szabo G (2012) Induction of Bcl-3 by acute binge alcohol results in toll-like receptor 4/LPS tolerance. J Leukoc Biol 92:611–620

    CAS  PubMed Central  PubMed  Google Scholar 

  35. Pang M, Bala S, Kodys K, Catalano D, Szabo G (2011) Inhibition of TLR8- and TLR4-induced Type I IFN induction by alcohol is different from its effects on inflammatory cytokine production in monocytes. BMC Immunol 12:55

    CAS  PubMed Central  PubMed  Google Scholar 

  36. Norkina O, Dolganiuc A, Catalano D, Kodys K, Mandrekar P, Syed A, Efros M, Szabo G (2008) Acute alcohol intake induces SOCS1 and SOCS3 and inhibits cytokine-induced STAT1 and STAT3 signaling in human monocytes. Alcohol Clin Exp Res 32:1565–1573

    CAS  PubMed Central  PubMed  Google Scholar 

  37. Ye L, Wang S, Wang X, Zhou Y, Li J, Persidsky Y, Ho W (2010) Alcohol impairs interferon signaling and enhances full cycle hepatitis C virus JFH-1 infection of human hepatocytes. Drug Alcohol Depend 112:107–116

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, Gale M Jr, Rosen HR (2013) Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. PLoS Pathog 9:e1003316

    CAS  PubMed Central  PubMed  Google Scholar 

  39. Liu HM, Gale M (2010) Hepatitis C virus evasion from RIG-I-dependent hepatic innate immunity. Gastroenterol Res Pract 2010:548390

    PubMed Central  PubMed  Google Scholar 

  40. Zhang S, Kodys K, Li K, Szabo G (2013) Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. Gastroenterology 144(414–425):e7

    PubMed  Google Scholar 

  41. Nitta S, Sakamoto N, Nakagawa M, Kakinuma S, Mishima K, Kusano-Kitazume A, Kiyohashi K, Murakawa M, Nishimura-Sakurai Y, Azuma S, Tasaka-Fujita M, Asahina Y, Yoneyama M, Fujita T, Watanabe M (2013) Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology 57:46–58

    CAS  PubMed  Google Scholar 

  42. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M Jr, Lemon SM (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 102:2992–2997

    CAS  PubMed Central  PubMed  Google Scholar 

  43. Pawlotsky JM (2013) Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 369:321–342

    CAS  PubMed  Google Scholar 

  44. Shah N, Pierce T, Kowdley KV (2013) Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 22:1107–1121

    CAS  PubMed  Google Scholar 

  45. Chou R, Hartung D, Rahman B, Wasson N, Cottrell EB, Fu R (2013) Comparative effectiveness of antiviral treatment for hepatitis C virus infection in adults: a systematic review. Ann Intern Med 158:114–123

    PubMed  Google Scholar 

  46. Singal AK, Anand BS (2007) Mechanisms of synergy between alcohol and hepatitis C virus. J Clin Gastroenterol 41:761–772

    PubMed  Google Scholar 

  47. Siu L, Foont J, Wands JR (2009) Hepatitis C virus and alcohol. Semin Liver Dis 29:188–199

    CAS  PubMed Central  PubMed  Google Scholar 

  48. Shuper PA, Neuman M, Kanteres F, Baliunas D, Joharchi N, Rehm J (2010) Causal considerations on alcohol and HIV/AIDS—a systematic review. Alcohol Alcohol 45:159–166

    PubMed  Google Scholar 

  49. Molina PE, Happel KI, Zhang P, Kolls JK, Nelson S (2010) Focus on: alcohol and the immune system. Alcohol Res Health 33:97–108

    PubMed Central  PubMed  Google Scholar 

  50. Jerrells TR, Pavlik JA, Devasure J, Vidlak D, Costello A, Strachota JM, Wyatt TA (2007) Association of chronic alcohol consumption and increased susceptibility to and pathogenic effects of pulmonary infection with respiratory syncytial virus in mice. Alcohol 41:357–369

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Le Strat Y, Grant BF, Ramoz N, Gorwood P (2010) A new definition of early age at onset in alcohol dependence. Drug Alcohol Depend 108:43–48

    PubMed  Google Scholar 

  52. Plumlee CR, Lazaro CA, Fausto N, Polyak SJ (2005) Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J 2:89

    PubMed Central  PubMed  Google Scholar 

  53. Imran M, Waheed Y, Manzoor S, Bilal M, Ashraf W, Ali M, Ashraf M (2012) Interaction of Hepatitis C virus proteins with pattern recognition receptors. Virol J 9:126

    CAS  PubMed Central  PubMed  Google Scholar 

  54. Chung H, Watanabe T, Kudo M, Chiba T (2010) Hepatitis C virus core protein induces homotolerance and cross-tolerance to Toll-like receptor ligands by activation of Toll-like receptor 2. J Infect Dis 202:853–861

    CAS  PubMed  Google Scholar 

  55. Chang S, Dolganiuc A, Szabo G (2007) Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 82:479–487

    CAS  PubMed  Google Scholar 

  56. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G (2004) Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology 127:1513–1524

    CAS  PubMed  Google Scholar 

  57. Shrivastava S, Mukherjee A, Ray R, Ray RB (2013) Hepatitis C virus induces interleukin-1beta (IL-1beta)/IL-18 in circulatory and resident liver macrophages. J Virol 87:12284–12290

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, Delker DA, Jo J, Bertoletti A, Hagedorn CH, Gale M Jr (2013) IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog 9:e1003330

    CAS  PubMed Central  PubMed  Google Scholar 

  59. Hosomura N, Kono H, Tsuchiya M, Ishii K, Ogiku M, Matsuda M, Fujii H (2011) HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci 56:1057–1064

    PubMed  Google Scholar 

  60. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, Mandrekar P, Szabo G (2007) Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 133:1627–1636

    CAS  PubMed Central  PubMed  Google Scholar 

  61. Bala S, Tilahun Y, Taha O, Alao H, Kodys K, Catalano D, Szabo G (2012) Increased microRNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med 10:151

    CAS  PubMed Central  PubMed  Google Scholar 

  62. Coulouarn C, Corlu A, Glaise D, Guenon I, Thorgeirsson SS, Clement B (2012) Hepatocyte-stellate cell cross-talk in the liver engenders a permissive inflammatory microenvironment that drives progression in hepatocellular carcinoma. Cancer Res 72:2533–2542

    CAS  PubMed Central  PubMed  Google Scholar 

  63. Brownell J, Polyak SJ (2013) Molecular pathways: hepatitis C virus, CXCL10, and the inflammatory road to liver cancer. Clin Cancer Res 19:1347–1352

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Wang HJ, Zakhari S, Jung MK (2010) Alcohol, inflammation, and gut-liver-brain interactions in tissue damage and disease development. World J Gastroenterol 16:1304–1313

    CAS  PubMed Central  PubMed  Google Scholar 

  65. Szabo G (2010) The 40th anniversary of the National Institute on Alcoholism and Alcohol Abuse: the impact on liver disease. Hepatology 52:10–12

    PubMed  Google Scholar 

  66. Szabo G, Mandrekar P (2010) Focus on: alcohol and the liver. Alcohol Res Health 33:87–96

    PubMed Central  PubMed  Google Scholar 

  67. Inokuchi S, Tsukamoto H, Park E, Liu ZX, Brenner DA, Seki E (2011) Toll-like receptor 4 mediates alcohol-induced steatohepatitis through bone marrow-derived and endogenous liver cells in mice. Alcohol Clin Exp Res 35:1509–1518

    CAS  PubMed Central  PubMed  Google Scholar 

  68. Schafer C, Parlesak A, Schutt C, Bode JC, Bode C (2002) Concentrations of lipopolysaccharide-binding protein, bactericidal/permeability-increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease. Alcohol Alcohol 37:81–86

    CAS  PubMed  Google Scholar 

  69. Blair GE, Cook GP (2008) Cancer and the immune system: an overview. Oncogene 27:5868

    CAS  PubMed  Google Scholar 

  70. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15

    CAS  PubMed  Google Scholar 

  71. Zhang T, Guo CJ, Douglas SD, Metzger DS, O’brien CP, Li Y, Wang YJ, Wang X, Ho WZ (2005) Alcohol suppresses IL-2-induced CC chemokine production by natural killer cells. Alcohol Clin Exp Res 29:1559–1567

    CAS  PubMed Central  PubMed  Google Scholar 

  72. Ben-Eliyahu S, Page GG, Yirmiya R, Taylor AN (1996) Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 2:457–460

    CAS  PubMed  Google Scholar 

  73. Zhang H, Meadows GG (2008) Chronic alcohol consumption perturbs the balance between thymus-derived and bone marrow-derived natural killer cells in the spleen. J Leukoc Biol 83:41–47

    CAS  PubMed  Google Scholar 

  74. Boyadjieva NI, Chaturvedi K, Poplawski MM, Sarkar DK (2004) Opioid antagonist naltrexone disrupts feedback interaction between mu and delta opioid receptors in splenocytes to prevent alcohol inhibition of NK cell function. J Immunol 173:42–49

    CAS  PubMed  Google Scholar 

  75. Jeong WI, Park O, Gao B (2008) Abrogation of the antifibrotic effects of natural killer cells/interferon-gamma contributes to alcohol acceleration of liver fibrosis. Gastroenterology 134:248–258

    CAS  PubMed Central  PubMed  Google Scholar 

  76. Jeong WI, Gao B (2008) Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol 23(Suppl 1):S112–S118

    CAS  PubMed Central  PubMed  Google Scholar 

  77. Zhang H, Meadows GG (2009) Exogenous IL-15 in combination with IL-15R alpha rescues natural killer cells from apoptosis induced by chronic alcohol consumption. Alcohol Clin Exp Res 33:419–427

    CAS  PubMed Central  PubMed  Google Scholar 

  78. Ljunggren HG, Karre K (1990) In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol Today 11:237–244

    CAS  PubMed  Google Scholar 

  79. Harrison RJ, Ettorre A, Little AM, Khakoo SI (2010) Association of NKG2A with treatment for chronic hepatitis C virus infection. Clin Exp Immunol 161:306–314

    CAS  PubMed Central  PubMed  Google Scholar 

  80. Ahlenstiel G, Edlich B, Hogdal LJ, Rotman Y, Noureddin M, Feld JJ, Holz LE, Titerence RH, Liang TJ, Rehermann B (2011) Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 141:1231–1239e1-2

    CAS  PubMed Central  PubMed  Google Scholar 

  81. Amadei B, Urbani S, Cazaly A, Fisicaro P, Zerbini A, Ahmed P, Missale G, Ferrari C, Khakoo SI (2010) Activation of natural killer cells during acute infection with hepatitis C virus. Gastroenterology 138:1536–1545

    CAS  PubMed Central  PubMed  Google Scholar 

  82. Zhang S, Saha B, Kodys K, Szabo G (2013) IFN-gamma production by human natural killer cells in response to HCV-infected hepatoma cells is dependent on accessory cells. J Hepatol 59:442–449

    CAS  PubMed Central  PubMed  Google Scholar 

  83. Dessouki O, Kamiya Y, Nagahama H, Tanaka M, Suzu S, Sasaki Y, Okada S (2010) Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment. Biochem Biophys Res Commun 393:331–337

    CAS  PubMed  Google Scholar 

  84. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, Feld JJ, Liang TJ, Rotman Y, Rehermann B (2012) Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. Hepatology 55:39–48

    CAS  PubMed Central  PubMed  Google Scholar 

  85. Gonzalez VD, Falconer K, Michaelsson J, Moll M, Reichard O, Alaeus A, Sandberg JK (2008) Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol 128:46–56

    CAS  PubMed  Google Scholar 

  86. Gao B, Radaeva S, Jeong WI (2007) Activation of natural killer cells inhibits liver fibrosis: a novel strategy to treat liver fibrosis. Expert Rev Gastroenterol Hepatol 1:173–180

    CAS  PubMed  Google Scholar 

  87. Gao B, Radaeva S, Park O (2009) Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 86:513–528

    CAS  PubMed Central  PubMed  Google Scholar 

  88. Arteel GE (2008) Silencing a killer among us: ethanol impairs immune surveillance of activated stellate cells by natural killer cells. Gastroenterology 134:351–353

    CAS  PubMed Central  PubMed  Google Scholar 

  89. Szabo G, Dolganiuc A (2005) Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 210:237–247

    CAS  PubMed  Google Scholar 

  90. Szabo G, Dolganiuc A, Mandrekar P, White B (2004) Inhibition of antigen-presenting cell functions by alcohol: implications for hepatitis C virus infection. Alcohol 33:241–249

    CAS  PubMed  Google Scholar 

  91. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Mandrekar P, Szabo G (2003) Additive inhibition of dendritic cell allostimulatory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. Alcohol Clin Exp Res 27:1023–1031

    CAS  PubMed  Google Scholar 

  92. Dolganiuc A, Kodys K, Kopasz A, Marshall C, Do T, Romics L Jr, Mandrekar P, Zapp M, Szabo G (2003) Hepatitis C virus core and nonstructural protein 3 proteins induce pro- and anti-inflammatory cytokines and inhibit dendritic cell differentiation. J Immunol 170:5615–5624

    CAS  PubMed  Google Scholar 

  93. Mandrekar P, Catalano D, Dolganiuc A, Kodys K, Szabo G (2004) Inhibition of myeloid dendritic cell accessory cell function and induction of T cell anergy by alcohol correlates with decreased IL-12 production. J Immunol 173:3398–3407

    CAS  PubMed  Google Scholar 

  94. Golden-Mason L, Palmer B, Klarquist J, Mengshol JA, Castelblanco N, Rosen HR (2007) Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol 81:9249–9258

    CAS  PubMed Central  PubMed  Google Scholar 

  95. Saha B, Choudhary MC, Sarin SK (2013) Expression of inhibitory markers is increased on effector memory T cells during hepatitis C virus/HIV coinfection as compared to hepatitis C virus or HIV monoinfection. AIDS 27:2191–2200

    CAS  PubMed  Google Scholar 

  96. Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, Cavallo MC, Orlandini A, Missale G, Ferrari C (2008) Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol 48:548–558

    CAS  PubMed  Google Scholar 

  97. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, Gretch DR, Rosen HR (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J Clin Invest 120:4546–4557

    CAS  PubMed Central  PubMed  Google Scholar 

  98. Gondois-Rey F, Dental C, Halfon P, Baumert TF, Olive D, Hirsch I (2009) Hepatitis C virus is a weak inducer of interferon alpha in plasmacytoid dendritic cells in comparison with influenza and human herpesvirus type-1. PLoS One 4:e4319

    PubMed Central  PubMed  Google Scholar 

  99. Liu BS, Groothuismink ZM, Janssen HL, Boonstra A (2011) Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukoc Biol 89:981–988

    CAS  PubMed  Google Scholar 

  100. Wegert M, La Monica N, Tripodi M, Adler G, Dikopoulos N (2009) Impaired interferon type I signalling in the liver modulates the hepatic acute phase response in hepatitis C virus transgenic mice. J Hepatol 51:271–278

    CAS  PubMed  Google Scholar 

  101. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA (2005) Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 280:37481–37488

    CAS  PubMed  Google Scholar 

  102. Korenaga M, Okuda M, Otani K, Wang T, Li Y, Weinman SA (2005) Mitochondrial dysfunction in hepatitis C. J Clin Gastroenterol 39:S162–S166

    CAS  PubMed  Google Scholar 

  103. Mas VR, Fassnacht R, Archer KJ, Maluf D (2010) Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis. Mol Med 16:287–297

    CAS  PubMed Central  PubMed  Google Scholar 

  104. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, Matsuura Y, Kimura S, Miyamura T, Koike K (1998) The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 4:1065–1067

    CAS  PubMed  Google Scholar 

  105. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K (2001) Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 61:4365–4370

    CAS  PubMed  Google Scholar 

  106. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA (2002) Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122:366–375

    CAS  PubMed  Google Scholar 

  107. Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, Majano PL, Benedicto I, Rosado JA, Salido GM, Gonzalez-Gallego J (2009) Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol 50:872–882

    CAS  PubMed  Google Scholar 

  108. Otani K, Korenaga M, Beard MR, Li K, Qian T, Showalter LA, Singh AK, Wang T, Weinman SA (2005) Hepatitis C virus core protein, cytochrome P450 2E1, and alcohol produce combined mitochondrial injury and cytotoxicity in hepatoma cells. Gastroenterology 128:96–107

    CAS  PubMed  Google Scholar 

  109. Dolganiuc A, Bakis G, Kodys K, Mandrekar P, Szabo G (2006) Acute ethanol treatment modulates Toll-like receptor-4 association with lipid rafts. Alcohol Clin Exp Res 30:76–85

    CAS  PubMed  Google Scholar 

  110. Testro AG, Gow PJ, Angus PW, Wongseelashote S, Skinner N, Markovska V, Visvanathan K (2010) Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol 52:199–205

    CAS  PubMed  Google Scholar 

  111. Szabo G, Velayudham A, Romics L Jr, Mandrekar P (2005) Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 29:140S–145S

    CAS  PubMed  Google Scholar 

  112. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, Seki E, Deshaies R, Miyake K, Lai MM (2009) Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A 106:1548–1553

    CAS  PubMed Central  PubMed  Google Scholar 

  113. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917–1920

    CAS  PubMed  Google Scholar 

  114. Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, Xu Y, Ma Q, Yang Z, Zhang Q, Ma L, Liu J, Xu S, Yan X, Bie P, Cui Y, Bian XW, Qian C (2012) Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 56:1004–1014

    CAS  PubMed  Google Scholar 

  115. Sun C, Sun L, Jiang K, Gao DM, Kang XN, Wang C, Zhang S, Huang S, Qin X, Li Y, Liu YK (2013) NANOG promotes liver cancer cell invasion by inducing epithelial-mesenchymal transition through NODAL/SMAD3 signaling pathway. Int J Biochem Cell Biol 45:1099–1108

    CAS  PubMed  Google Scholar 

  116. Hara Y, Hino K, Okuda M, Furutani T, Hidaka I, Yamaguchi Y, Korenaga M, Li K, Weinman SA, Lemon SM, Okita K (2006) Hepatitis C virus core protein inhibits deoxycholic acid-mediated apoptosis despite generating mitochondrial reactive oxygen species. J Gastroenterol 41:257–268

    CAS  PubMed  Google Scholar 

  117. Gong G, Waris G, Tanveer R, Siddiqui A (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 98:9599–9604

    CAS  PubMed Central  PubMed  Google Scholar 

  118. Brault C, Levy PL, Bartosch B (2013) Hepatitis C virus-induced mitochondrial dysfunctions. Viruses 5:954–980

    CAS  PubMed Central  PubMed  Google Scholar 

  119. Hou W, Bukong TN, Kodys K, Szabo G (2013) Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res 37:599–608

    CAS  PubMed Central  PubMed  Google Scholar 

  120. Seronello S, Ito C, Wakita T, Choi J (2010) Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+. J Biol Chem 285:845–854

    CAS  PubMed Central  PubMed  Google Scholar 

  121. Lee HS, Yoon JH, Kamimura S, Iwata K, Watanabe H, Kim CY (1997) Lack of association of cytochrome P450 2E1 genetic polymorphisms with the risk of human hepatocellular carcinoma. Int J Cancer 71:737–740

    CAS  PubMed  Google Scholar 

  122. Hirose Y, Naito Z, Kato S, Onda M, Sugisaki Y (2002) Immunohistochemical study of CYP2E1 in hepatocellular carcinoma carcinogenesis: examination with newly prepared anti-human CYP2E1 antibody. J Nippon Med Sch 69:243–251

    CAS  PubMed  Google Scholar 

  123. Liu C, Wang H, Pan C, Shen J, Liang Y (2012) CYP2E1 PstI/RsaI polymorphism and interaction with alcohol consumption in hepatocellular carcinoma susceptibility: evidence from 1,661 cases and 2,317 controls. Tumour Biol 33:979–984

    CAS  PubMed  Google Scholar 

  124. Solit DB, Chiosis G (2008) Development and application of Hsp90 inhibitors. Drug Discov Today 13:38–43

    CAS  PubMed  Google Scholar 

  125. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537–549

    CAS  PubMed  Google Scholar 

  126. Schlesinger MJ (1990) Heat shock proteins. J Biol Chem 265:12111–12114

    CAS  PubMed  Google Scholar 

  127. Zhao R, Houry WA (2005) Hsp90: a chaperone for protein folding and gene regulation. Biochem Cell Biol 83:703–710

    CAS  PubMed  Google Scholar 

  128. Bohonowych JE, Gopal U, Isaacs JS (2010) Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol 2010:412985

    CAS  PubMed Central  PubMed  Google Scholar 

  129. Freeman BC, Yamamoto KR (2002) Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 296:2232–2235

    CAS  PubMed  Google Scholar 

  130. Tariq M, Nussbaumer U, Chen Y, Beisel C, Paro R (2009) Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression. Proc Natl Acad Sci U S A 106:1157–1162

    CAS  PubMed Central  PubMed  Google Scholar 

  131. Bagatell R, Whitesell L (2004) Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol Cancer Ther 3:1021–1030

    CAS  PubMed  Google Scholar 

  132. Eustace BK, Sakurai T, Stewart JK, Yimlamai D, Unger C, Zehetmeier C, Lain B, Torella C, Henning SW, Beste G, Scroggins BT, Neckers L, Ilag LL, Jay DG (2004) Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 6:507–514

    CAS  PubMed  Google Scholar 

  133. Parkin DM (2006) The global health burden of infection-associated cancers in the year 2002. Int J Cancer 118:3030–3044

    CAS  PubMed  Google Scholar 

  134. De Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615

    PubMed  Google Scholar 

  135. McGivern DR, Lemon SM (2011) Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 30:1969–1983

    CAS  PubMed Central  PubMed  Google Scholar 

  136. Mandrekar P, Catalano D, Jeliazkova V, Kodys K (2008) Alcohol exposure regulates heat shock transcription factor binding and heat shock proteins 70 and 90 in monocytes and macrophages: implication for TNF-alpha regulation. J Leukoc Biol 84:1335–1345

    CAS  PubMed Central  PubMed  Google Scholar 

  137. Bukong TN, Hou W, Kodys K, Szabo G (2013) Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology 57:70–80

    CAS  PubMed Central  PubMed  Google Scholar 

  138. Ambade A, Catalano D, Lim A, Mandrekar P (2012) Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice. Hepatology 55:1585–1595

    CAS  PubMed Central  PubMed  Google Scholar 

  139. Sun Y, Zang Z, Xu X, Zhang Z, Zhong L, Zan W, Zhao Y, Sun L (2010) Differential proteomics identification of HSP90 as potential serum biomarker in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry. Int J Mol Sci 11:1423–1433

    CAS  PubMed Central  PubMed  Google Scholar 

  140. Breinig M, Caldas-Lopes E, Goeppert B, Malz M, Rieker R, Bergmann F, Schirmacher P, Mayer M, Chiosis G, Kern MA (2009) Targeting heat shock protein 90 with non-quinone inhibitors: a novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50:102–112

    CAS  PubMed  Google Scholar 

  141. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F (2005) Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 42:1310–1319

    CAS  PubMed  Google Scholar 

  142. Taguwa S, Kambara H, Omori H, Tani H, Abe T, Mori Y, Suzuki T, Yoshimori T, Moriishi K, Matsuura Y (2009) Cochaperone activity of human butyrate-induced transcript 1 facilitates hepatitis C virus replication through an Hsp90-dependent pathway. J Virol 83:10427–10436

    CAS  PubMed Central  PubMed  Google Scholar 

  143. Nakagawa S, Umehara T, Matsuda C, Kuge S, Sudoh M, Kohara M (2007) Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem Biophys Res Commun 353:882–888

    CAS  PubMed  Google Scholar 

  144. Okamoto T, Nishimura Y, Ichimura T, Suzuki K, Miyamura T, Suzuki T, Moriishi K, Matsuura Y (2006) Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J 25:5015–5025

    CAS  PubMed Central  PubMed  Google Scholar 

  145. Ujino S, Nishitsuji H, Sugiyama R, Suzuki H, Hishiki T, Sugiyama K, Shimotohno K, Takaku H (2012) The interaction between human initiation factor eIF3 subunit c and heat-shock protein 90: a necessary factor for translation mediated by the hepatitis C virus internal ribosome entry site. Virus Res 163:390–395

    CAS  PubMed  Google Scholar 

  146. Ujino S, Yamaguchi S, Shimotohno K, Takaku H (2009) Heat-shock protein 90 is essential for stabilization of the hepatitis C virus nonstructural protein NS3. J Biol Chem 284:6841–6846

    CAS  PubMed Central  PubMed  Google Scholar 

  147. Varmus HE (1984) The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553–612

    CAS  PubMed  Google Scholar 

  148. Okamoto T, Omori H, Kaname Y, Abe T, Nishimura Y, Suzuki T, Miyamura T, Yoshimori T, Moriishi K, Matsuura Y (2008) A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication. J Virol 82:3480–3489

    CAS  PubMed Central  PubMed  Google Scholar 

  149. Takayama S, Reed JC, Homma S (2003) Heat-shock proteins as regulators of apoptosis. Oncogene 22:9041–9047

    CAS  PubMed  Google Scholar 

  150. Lanneau D, Brunet M, Frisan E, Solary E, Fontenay M, Garrido C (2008) Heat shock proteins: essential proteins for apoptosis regulation. J Cell Mol Med 12:743–761

    CAS  PubMed  Google Scholar 

  151. Bai L, Xu S, Chen W, Li Z, Wang X, Tang H, Lin Y (2011) Blocking Nf-kappaB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death. Apoptosis 16:45–54

    CAS  PubMed Central  PubMed  Google Scholar 

  152. Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y (2012) The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Cell Biol Int 36:893–899

    CAS  PubMed  Google Scholar 

  153. Lang SA, Moser C, Fichnter-Feigl S, Schachtschneider P, Hellerbrand C, Schmitz V, Schlitt HJ, Geissler EK, Stoeltzing O (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49:523–532

    CAS  PubMed  Google Scholar 

  154. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minguez B, Tsai HW, Ward SC, Thung S, Friedman SL, Llovet JM (2012) Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 56:1343–1350

    CAS  PubMed Central  PubMed  Google Scholar 

  155. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, Degott C, Valla D, Erlinger S, Rueff B (1998) Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 27:1717–1722

    CAS  PubMed  Google Scholar 

  156. Safdar K, Schiff ER (2004) Alcohol and hepatitis C. Semin Liver Dis 24:305–315

    PubMed  Google Scholar 

  157. Anand BS, Thornby J (2005) Alcohol has no effect on hepatitis C virus replication: a meta-analysis. Gut 54:1468–1472

    CAS  PubMed Central  PubMed  Google Scholar 

  158. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R, Zaret KS, Taylor JM (2004) miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1:106–113

    CAS  PubMed  Google Scholar 

  159. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T (2002) Identification of tissue-specific microRNAs from mouse. Curr Biol 12:735–739

    CAS  PubMed  Google Scholar 

  160. Jopling CL (2008) Regulation of hepatitis C virus by microRNA-122. Biochem Soc Trans 36:1220–1223

    CAS  PubMed  Google Scholar 

  161. Jopling CL, Schutz S, Sarnow P (2008) Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 4:77–85

    CAS  PubMed Central  PubMed  Google Scholar 

  162. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P (2005) Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577–1581

    CAS  PubMed  Google Scholar 

  163. Machlin ES, Sarnow P, Sagan SM (2011) Masking the 5′ terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 108:3193–3198

    CAS  PubMed Central  PubMed  Google Scholar 

  164. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS (2009) Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28:3526–3536

    CAS  PubMed Central  PubMed  Google Scholar 

  165. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K (2006) Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 99:671–678

    CAS  PubMed Central  PubMed  Google Scholar 

  166. Bala S, Szabo G (2012) MicroRNA signature in alcoholic liver disease. Int J Hepatol 2012:498232

    PubMed Central  PubMed  Google Scholar 

  167. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, Hood LE, Galas DJ (2009) Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 106:4402–4407

    CAS  PubMed Central  PubMed  Google Scholar 

  168. Laterza OF, Scott MG, Garrett-Engele PW, Korenblat KM, Lockwood CM (2013) Circulating miR-122 as a potential biomarker of liver disease. Biomark Med 7:205–210

    CAS  PubMed  Google Scholar 

  169. Van Der Meer AJ, Farid WR, Sonneveld MJ, De Ruiter PE, Boonstra A, Van Vuuren AJ, Verheij J, Hansen BE, De Knegt RJ, Van Der Laan LJ, Janssen HL (2013) Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat 20:158–166

    PubMed  Google Scholar 

  170. Szabo G, Bala S (2013) MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 10:542–552

    CAS  PubMed Central  PubMed  Google Scholar 

  171. Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, Huang Y, Chen HC, Lee CH, Tsai TF, Hsu MT, Wu JC, Huang HD, Shiao MS, Hsiao M, Tsou AP (2012) MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 122:2884–2897

    CAS  PubMed Central  PubMed  Google Scholar 

  172. Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122:2871–2883

    CAS  PubMed Central  PubMed  Google Scholar 

  173. Bai S, Nasser MW, Wang B, Hsu SH, Datta J, Kutay H, Yadav A, Nuovo G, Kumar P, Ghoshal K (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284:32015–32027

    CAS  PubMed Central  PubMed  Google Scholar 

  174. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, Kauppinen S, Orum H (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198–201

    CAS  PubMed Central  PubMed  Google Scholar 

  175. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, Van Der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR (2013) Treatment of HCV infection by targeting microRNA. N Engl J Med 368:1685–1694

    CAS  PubMed  Google Scholar 

  176. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T, Douek DC (2011) Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 141:1220–1230e1-3

    PubMed Central  PubMed  Google Scholar 

  177. Caradonna L, Mastronardi ML, Magrone T, Cozzolongo R, Cuppone R, Manghisi OG, Caccavo D, Pellegrino NM, Amoroso A, Jirillo E, Amati L (2002) Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection. Curr Pharm Des 8:995–1005

    CAS  PubMed  Google Scholar 

  178. Welsch C, Jesudian A, Zeuzem S, Jacobson I (2012) New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut 61(Suppl 1):i36–i46

    CAS  PubMed  Google Scholar 

  179. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM (2012) Antiviral strategies in hepatitis C virus infection. J Hepatol 56(Suppl 1):S88–S100

    CAS  PubMed  Google Scholar 

  180. Klibanov OM, Williams SH, Smith LS, Olin JL, Vickery SB (2011) Telaprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy 31:951–974

    CAS  PubMed  Google Scholar 

  181. Klibanov OM, Vickery SB, Olin JL, Smith LS, Williams SH (2012) Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C. Pharmacotherapy 32:173–190

    CAS  PubMed  Google Scholar 

  182. Schinazi R, Halfon P, Marcellin P, Asselah T (2014) HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 34(Suppl 1):69–78

    CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The authors declare there are no conflicts of interest.

Grant Acknowledgment  5R37AA014372-10

Author information

Authors and Affiliations

  1. Department of Medicine, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA, 01605, USA

    Gyongyi Szabo M.D., Ph.D., Banishree Saha & Terence N. Bukong

Authors
  1. Gyongyi Szabo M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Banishree Saha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Terence N. Bukong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gyongyi Szabo M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut, USA

    Vasilis Vasiliou

  2. Distilled Spirits Council of the United States, Washington, District of Columbia, USA

    Samir Zakhari

  3. Centre of Alcohol Research, University of Heidelberg, Germany and Salem Medical Centre, Heidelberg, Germany

    Helmut K. Seitz

  4. Department of Pathology, Anatomy, & Cell, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

    Jan B. Hoek

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this paper

Cite this paper

Szabo, G., Saha, B., Bukong, T.N. (2015). Alcohol and HCV: Implications for Liver Cancer. In: Vasiliou, V., Zakhari, S., Seitz, H., Hoek, J. (eds) Biological Basis of Alcohol-Induced Cancer. Advances in Experimental Medicine and Biology, vol 815. Springer, Cham. https://doi.org/10.1007/978-3-319-09614-8_12

Download citation

Publish with us

Policies and ethics

Search

Navigation